Back to Search
Start Over
A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
- Source :
- Clinical Case Reports, Vol 10, Iss 7, Pp n/a-n/a (2022)
- Publication Year :
- 2022
- Publisher :
- Wiley, 2022.
-
Abstract
- Abstract An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5‐month progression‐free survival. Atez/Bev might exhibit efficacy for CHC patients.
Details
- Language :
- English
- ISSN :
- 20500904
- Volume :
- 10
- Issue :
- 7
- Database :
- Directory of Open Access Journals
- Journal :
- Clinical Case Reports
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.2cd1c635ef1d44faa870f54f525fdf8d
- Document Type :
- article
- Full Text :
- https://doi.org/10.1002/ccr3.6129